NIH R01 · 2024
Project Summary: Currently, there are over 40 million people living with HIV-1 worldwide. Although combination antiretroviral therapy (cART) has improved the health and lifespan of millions of those living with HIV-1, long-term use of antiretrovirals coupled with limited penetration of some of these medications into the CNS, is often accompanied with neurocognitive impairments in at least 50% of infected individuals, commonly referred to as NeuroHIV. Additionally, while cART can successfully suppress peripheral viremia, persistence of cytotoxicity viral protein such as Transactivator of transcription (Tat) in tissues such as the brain, remains a significant concern. Adding further…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.